Guided Therapeutics annual free cash flow
2016
2019
2020
2021
2022
2023
2024
2025
Guided Therapeutics Free Cash Flow (FCF) History (GTHP)
Guided Therapeutics reported −$1.1M in free cash flow for fiscal 2025, an increase of $49,000 from the previous fiscal year, with a free cash flow margin of −139.50%.
View full Guided Therapeutics company overviewGuided Therapeutics free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | −$1.1M | $49,000 | — | −139.50% |
| 2024 | 2024-12-31 | −$1.1M | $627,000 | — | −15985.71% |
| 2023 | 2023-12-31 | −$1.7M | −$236,000 | — | −1781.63% |
| 2022 | 2022-12-31 | −$1.5M | $96,000 | — | −11615.38% |
| 2021 | 2021-12-31 | −$1.6M | $270,000 | — | −1982.72% |
| 2020 | 2020-12-31 | −$1.9M | −$1.1M | — | −1839.22% |
| 2019 | 2019-12-31 | −$806,000 | $996,000 | — | −2238.89% |
| 2016 | 2016-12-31 | −$1.8M | — | — | — |
Guided Therapeutics quarterly free cash flow
Q3.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q4 2023 | 2023-12-31 | −$336,000 | $6,000 | — | −1050.00% |
| Q3 2023 | 2023-09-30 | −$473,000 | $142,000 | — | — |
| Q2 2023 | 2023-06-30 | −$438,000 | −$72,000 | — | −995.45% |
| Q1 2023 | 2023-03-31 | −$499,000 | −$306,000 | — | −2268.18% |
| Q4 2022 | 2022-12-31 | −$342,000 | −$497,000 | — | — |
| Q3 2022 | 2022-09-30 | −$615,000 | $129,000 | — | −20500.00% |
| Q2 2022 | 2022-06-30 | −$366,000 | $330,000 | — | −7320.00% |
| Q1 2022 | 2022-03-31 | −$193,000 | $128,000 | — | −3860.00% |
| Q4 2021 | 2021-12-31 | $155,000 | $486,000 | — | +258.33% |
| Q3 2021 | 2021-09-30 | −$744,000 | −$138,000 | — | −3915.79% |
| Q2 2021 | 2021-06-30 | −$696,000 | −$287,000 | — | −34800.00% |
| Q1 2021 | 2021-03-31 | −$321,000 | $209,000 | — | — |
| Q4 2020 | 2020-12-31 | −$331,000 | −$103,000 | — | −1324.00% |
| Q3 2020 | 2020-09-30 | −$606,000 | — | — | −787.01% |
| Q2 2020 | 2020-06-30 | −$409,000 | — | — | — |
| Q1 2020 | 2020-03-31 | −$530,000 | — | — | — |
| Q3 2019 | 2019-09-30 | −$228,000 | — | — | −22800.00% |
Guided Therapeutics free cash flow growth trends
Over the last five reported fiscal years, free cash flow grew from −$1.9M to −$1.1M, a net increase of $806,000. Guided Therapeutics's latest reported quarter, Q4 2023, generated −$336,000 in free cash flow, an increase of $6,000 year over year.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Guided Therapeutics filings at SEC.gov ↗